Neoplasms
BlueSky Vaccines’ mission is to fully exploit the potential of virotherapy against cancer.The company has developed delNS106, an influenza-based viral vector based on a deletion in its interferon (IFN) antagonist NS1.
Due to deletion in NS1, high levels of IFN are induced, which in turn lead to strong innate and adaptive immune responses capable of overcoming the immunosuppression created by cancers.
